Further studies should utilize randomized controlled trials to study patients with DM/obesity and multiple MACE risk factors over a longer time period to provide a clearer perspective on the specific clinical utility of CYP2C19 genetic testing in comparison to standard treatment. Here, CYP2C19 is linked to obesity due to melanocortin 4 receptor deficiency.